Literature DB >> 22451487

Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands.

Regina Goetz1, Mutsuko Ohnishi, Xunshan Ding, Hiroshi Kurosu, Lei Wang, Junko Akiyoshi, Jinghong Ma, Weiming Gai, Yisrael Sidis, Nelly Pitteloud, Makoto Kuro-O, Mohammed S Razzaque, Moosa Mohammadi.   

Abstract

It has been recently established that Klotho coreceptors associate with fibroblast growth factor (FGF) receptor tyrosine kinases (FGFRs) to enable signaling by endocrine-acting FGFs. However, the molecular interactions leading to FGF-FGFR-Klotho ternary complex formation remain incompletely understood. Here, we show that in contrast to αKlotho, βKlotho binds its cognate endocrine FGF ligand (FGF19 or FGF21) and FGFR independently through two distinct binding sites. FGF19 and FGF21 use their respective C-terminal tails to bind to a common binding site on βKlotho. Importantly, we also show that Klotho coreceptors engage a conserved hydrophobic groove in the immunoglobulin-like domain III (D3) of the "c" splice isoform of FGFR. Intriguingly, this hydrophobic groove is also used by ligands of the paracrine-acting FGF8 subfamily for receptor binding. Based on this binding site overlap, we conclude that while Klotho coreceptors enhance binding affinity of FGFR for endocrine FGFs, they actively suppress binding of FGF8 subfamily ligands to FGFR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451487      PMCID: PMC3347405          DOI: 10.1128/MCB.06603-11

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  74 in total

1.  Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.

Authors:  T Lundåsen; C Gälman; B Angelin; M Rudling
Journal:  J Intern Med       Date:  2006-12       Impact factor: 8.989

2.  Fibroblast growth factor 16 and 18 are expressed in human cardiovascular tissues and induce on endothelial cells migration but not proliferation.

Authors:  M Antoine; W Wirz; C G Tag; A M Gressner; M Wycislo; R Müller; P Kiefer
Journal:  Biochem Biophys Res Commun       Date:  2006-05-26       Impact factor: 3.575

3.  Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.

Authors:  Hiroshi Kurosu; Mihwa Choi; Yasushi Ogawa; Addie S Dickson; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Kevin P Rosenblatt; Steven A Kliewer; Makoto Kuro-o
Journal:  J Biol Chem       Date:  2007-07-10       Impact factor: 5.157

4.  Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis.

Authors:  Helen P Makarenkova; Matthew P Hoffman; Andrew Beenken; Anna V Eliseenkova; Robyn Meech; Cindy Tsau; Vaishali N Patel; Richard A Lang; Moosa Mohammadi
Journal:  Sci Signal       Date:  2009-09-15       Impact factor: 8.192

5.  Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members.

Authors:  Regina Goetz; Andrew Beenken; Omar A Ibrahimi; Juliya Kalinina; Shaun K Olsen; Anna V Eliseenkova; ChongFeng Xu; Thomas A Neubert; Fuming Zhang; Robert J Linhardt; Xijie Yu; Kenneth E White; Takeshi Inagaki; Steven A Kliewer; Masaya Yamamoto; Hiroshi Kurosu; Yasushi Ogawa; Makoto Kuro-o; Beate Lanske; Mohammed S Razzaque; Moosa Mohammadi
Journal:  Mol Cell Biol       Date:  2007-03-05       Impact factor: 4.272

6.  Klotho converts canonical FGF receptor into a specific receptor for FGF23.

Authors:  Itaru Urakawa; Yuji Yamazaki; Takashi Shimada; Kousuke Iijima; Hisashi Hasegawa; Katsuya Okawa; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Nature       Date:  2006-10-29       Impact factor: 49.962

7.  Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism.

Authors:  Nelly Pitteloud; Richard Quinton; Simon Pearce; Taneli Raivio; James Acierno; Andrew Dwyer; Lacey Plummer; Virginia Hughes; Stephanie Seminara; Yu-Zhu Cheng; Wei-Ping Li; Gavin Maccoll; Anna V Eliseenkova; Shaun K Olsen; Omar A Ibrahimi; Frances J Hayes; Paul Boepple; Janet E Hall; Pierre Bouloux; Moosa Mohammadi; William Crowley
Journal:  J Clin Invest       Date:  2007-01-18       Impact factor: 14.808

8.  BetaKlotho is required for metabolic activity of fibroblast growth factor 21.

Authors:  Yasushi Ogawa; Hiroshi Kurosu; Masaya Yamamoto; Animesh Nandi; Kevin P Rosenblatt; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Makoto Kuro-o
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-23       Impact factor: 11.205

9.  Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states.

Authors:  Michael K Badman; Pavlos Pissios; Adam R Kennedy; George Koukos; Jeffrey S Flier; Eleftheria Maratos-Flier
Journal:  Cell Metab       Date:  2007-06       Impact factor: 27.287

10.  Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21.

Authors:  Takeshi Inagaki; Paul Dutchak; Guixiang Zhao; Xunshan Ding; Laurent Gautron; Vinay Parameswara; Yong Li; Regina Goetz; Moosa Mohammadi; Victoria Esser; Joel K Elmquist; Robert D Gerard; Shawn C Burgess; Robert E Hammer; David J Mangelsdorf; Steven A Kliewer
Journal:  Cell Metab       Date:  2007-06       Impact factor: 27.287

View more
  32 in total

1.  Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor.

Authors:  Regina Goetz; Mutsuko Ohnishi; Serkan Kir; Hiroshi Kurosu; Lei Wang; Johanne Pastor; Jinghong Ma; Weiming Gai; Makoto Kuro-o; Mohammed S Razzaque; Moosa Mohammadi
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

2.  Can salivary phosphate levels be an early biomarker to monitor the evolvement of obesity?

Authors:  Mor-Li Hartman; Francisco Groppo; Mutsuko Ohnishi; J Max Goodson; Hatice Hasturk; Mary Tavares; Tina Yaskell; Constantino Floros; Kazem Behbehani; Mohammed S Razzaque
Journal:  Contrib Nephrol       Date:  2013-05-03       Impact factor: 1.580

3.  Structures of ligand-occupied β-Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity.

Authors:  Ekaterina S Kuzina; Peter Man-Un Ung; Jyotidarsini Mohanty; Francisco Tome; Jungyuen Choi; Els Pardon; Jan Steyaert; Irit Lax; Avner Schlessinger; Joseph Schlessinger; Sangwon Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-03       Impact factor: 11.205

Review 4.  αKlotho-FGF23 interactions and their role in kidney disease: a molecular insight.

Authors:  Edward R Smith; Stephen G Holt; Tim D Hewitson
Journal:  Cell Mol Life Sci       Date:  2019-07-26       Impact factor: 9.261

Review 5.  Dysregulation of phosphate metabolism and conditions associated with phosphate toxicity.

Authors:  Ronald B Brown; Mohammed S Razzaque
Journal:  Bonekey Rep       Date:  2015-06-03

Review 6.  Exploring mechanisms of FGF signalling through the lens of structural biology.

Authors:  Regina Goetz; Moosa Mohammadi
Journal:  Nat Rev Mol Cell Biol       Date:  2013-02-13       Impact factor: 94.444

Review 7.  Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology.

Authors:  Artur A Belov; Moosa Mohammadi
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-06-01       Impact factor: 10.005

Review 8.  Novel strategies and therapeutic options for the management of primary biliary cholangitis.

Authors:  Amardeep Khanna; David E Jones
Journal:  Therap Adv Gastroenterol       Date:  2017-09-07       Impact factor: 4.409

Review 9.  Fibroblast growth factors, old kids on the new block.

Authors:  Xiaokun Li; Cong Wang; Jian Xiao; Wallace L McKeehan; Fen Wang
Journal:  Semin Cell Dev Biol       Date:  2016-01-06       Impact factor: 7.727

10.  Thymic Epithelial Cell Support of Thymopoiesis Does Not Require Klotho.

Authors:  Yan Xing; Michelle J Smith; Christine A Goetz; Ron T McElmurry; Sarah L Parker; Dullei Min; Georg A Hollander; Kenneth I Weinberg; Jakub Tolar; Heather E Stefanski; Bruce R Blazar
Journal:  J Immunol       Date:  2018-10-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.